Medical Information Technology 10-K 25 Sep 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013
Document and Entity Information [Abstract]	'
Document Type	'10-K
Amendment Flag	'false
Document Period End Date	31-Dec-13
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'FY
Entity Registrant Name	'Medical Information Technology, Inc.
Entity Central Index Key	'0001011452
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Smaller Reporting Company
Entity Public Float	$0
Entity Common Stock, Shares Outstanding	37,140,854
Entity Well-known Seasoned Issuer	'No
Entity Voluntary Filers	'No
Entity Current Reporting Status	'Yes

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Financial Position [Abstract]	'	'	'
Common stock par value	$1	$1	$1
Common stock shares authorized	40,000,000	40,000,000	40,000,000
Common stock shares issued	37,115,854	36,785,201	36,541,348
Common stock shares outstanding	37,115,854	36,785,201	36,541,348

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Financial Position [Abstract]	'	'	'
Cash and equivalents	$42,481,997	$55,248,919	$59,847,020
Marketable securities	374,023,591	329,655,272	277,354,769
Trade receivables, net of reserve	50,638,740	48,250,846	56,059,016
Other receivables and prepaid	10,681,915	4,756,102	5,221,320
Current deferred tax asset	'	9,457,643	10,449,954
Current assets	477,826,243	447,368,782	408,932,079
Computer equipment	13,416,004	14,245,358	12,455,809
Furniture and fixtures	67,845,622	64,611,731	53,816,542
Buildings	225,948,241	189,997,036	183,411,627
Land	42,730,565	40,329,565	35,329,565
Accumulated depreciation	-133,505,381	-125,994,543	-116,553,548
Fixed assets	216,435,051	183,189,147	168,459,995
Other assets	15,317,332	16,630,096	18,709,864
Deferred Taxes	6,897,379	'	'
Total assets	716,476,005	647,188,025	596,101,938
Accounts payable	1,534,485	136,846	326,281
Taxes payable	2,054,703	4,863,915	5,213,475
Accrued expenses	53,976,811	55,098,832	51,027,125
Deferred revenue	35,503,326	31,512,690	41,030,877
Deferred taxes	18,649,594	'	'
Current liabilities	111,718,919	91,612,283	97,597,758
Tax reserves	18,512,277	17,779,175	12,564,037
Total liabilities	130,231,196	109,391,458	110,161,795
Common stock value	37,140,854	36,935,201	36,541,348
Additional paid-in capital	120,707,959	111,659,227	94,817,401
Retained income	355,301,450	333,185,351	308,404,621
Unrealized security gains, net of tax	73,094,546	56,016,788	46,176,773
Shareholder equity	586,244,809	537,796,567	485,940,143
Total liabilities and shareholder equity	$716,476,005	$647,188,025	$596,101,938

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Cash Flows [Abstract]	'	'	'
Net income	$133,328,172	$130,546,535	$124,001,302
Depreciation expense	12,934,306	11,810,960	10,740,217
Stock contributions to qualified profit sharing plan	1,125,000	6,750,000	5,160,000
Gain on sales of marketable securities	-11,906,501	-17,002,131	'
Gain on sale of fixed assets	-44,000	'	'
Deferred taxes on unrealized securities gain, net	'	-759,398	'
Change in trade receivables, net of reserve	-2,387,893	7,808,169	-2,591,106
Change in other receivables and prepaid	-5,925,814	465,218	'
Change in accounts payable	1,397,639	-189,435	-128,700
Change in taxes payable	-2,809,212	-349,560	1,497,240
Change in accrued expenses	-1,122,021	4,071,707	6,609,962
Change in deferred revenues	3,990,636	-9,518,187	1,187,847
Change in deferred taxes	706,226	987,312	-6,619,176
Change in tax reserves	733,102	5,220,138	1,065,000
Net cash from operating activities	130,019,640	139,841,329	140,922,586
Purchases of marketable securities	-20,937,683	-74,368,224	-70,824,104
Sales of marketable securities	26,057,254	49,669,265	'
Purchases of fixed assets	-46,196,210	-26,540,112	-10,644,343
Sales of fixed assets	60,000	'	'
Change in other assets	1,312,764	2,079,768	3,448,317
Acquisition of LSS, net of cash acquired	'	'	-12,801,142
Net cash used in investing activities	-39,703,875	-49,159,303	-90,821,272
Sales of common stock	8,129,385	10,485,679	9,407,360
Dividends paid	-111,212,072	-105,765,806	-97,451,639
Net cash used in financing activities	-103,082,687	-95,280,127	-88,044,279
Net change in cash and equivalents	-12,766,922	-4,598,101	-37,942,965
Cash and equivalents at beginning of year	55,248,919	59,847,020	97,789,985
Cash and equivalents at end of year	42,481,997	55,248,919	59,847,020
Supplemental Disclosure:	'	'	'
Cash paid for income taxes	$55,910,698	$73,547,193	$69,295,676

Consolidated_Statements_of_Inc

Consolidated Statements of Income and Comprehensive Income (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Product revenue	$278,319,450	$316,421,596	$288,351,034
Service revenue	301,326,007	281,417,191	256,873,350
Total revenues	579,645,457	597,838,787	545,224,384
Operations, development	292,369,166	283,479,355	245,924,776
Selling, G & A	123,660,776	122,753,583	116,314,384
Operating expense	416,029,942	406,232,938	362,239,160
Operating income	163,615,515	191,605,849	182,985,224
Other income	30,736,707	26,520,935	15,923,805
Other expense	7,028,101	6,021,904	7,001,738
Pretax income	187,324,121	212,104,880	191,907,291
State income tax	8,015,067	15,422,805	12,980,841
Federal income tax	45,980,882	66,135,540	54,925,148
Income tax	53,995,949	81,558,345	67,905,989
Net income	133,328,172	130,546,535	124,001,302
Change in net unrealized gains	17,077,757	9,840,015	17,642,621
Comprehensive income	$150,405,929	$140,386,550	$141,643,923

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholder Equity (USD $)	Total	Common Stock Paid-in capital	Retained income	Other Comprehensive	Shareholder equity
Balance, December 31, 2012 at Dec. 31, 2010	'	$116,791,389	$281,854,958	$28,534,152	$427,180,499
Issuance of common stock pursuant to Purchase Plan	'	9,407,360	'	'	9,407,360
Issuance of common stock pursuant to Profit Sharing Plan	'	5,160,000	'	'	5,160,000
Net income	124,001,302	'	124,001,302	'	124,001,302
Change in net unrealized gains	17,642,621	'	'	17,642,621	17,642,621
Dividends paid	-97,451,639	'	-97,451,639	'	-97,451,639
Balance, December 31, 2013 at Dec. 31, 2011	485,940,143	131,358,749	308,404,621	46,176,773	485,940,143
Issuance of common stock pursuant to Purchase Plan	'	10,485,679	'	'	10,485,679
Issuance of common stock pursuant to Profit Sharing Plan	'	6,750,000	'	'	6,750,000
Net income	130,546,535	'	130,546,535	'	130,546,535
Change in net unrealized gains	9,840,015	'	'	9,840,015	9,840,015
Dividends paid	-105,765,806	'	-105,765,806	'	-105,765,806
Balance, December 31, 2013 at Dec. 31, 2012	537,796,567	148,594,428	333,185,351	56,016,788	537,796,567
Issuance of common stock pursuant to Purchase Plan	'	8,129,385	'	'	8,129,385
Issuance of common stock pursuant to Profit Sharing Plan	'	1,125,000	'	'	1,125,000
Net income	133,328,172	'	133,328,172	'	133,328,172
Change in net unrealized gains	17,077,757	'	'	17,077,758	17,077,758
Dividends paid	-111,212,072	'	-111,212,073	'	-111,212,073
Balance, December 31, 2013 at Dec. 31, 2013	$586,244,809	$157,848,813	$355,301,450	$73,094,546	$586,244,809

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	Note 7. Accrued Expenses
	The components of accrued expenses for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Accrued bonuses	$43,750,000	$47,628,625	$45,985,000
	Accrued vacation	4,690,000	4,707,000	4,813,000
	Other	2,587,125	2,763,207	3,178,811
	Accrued expenses	$51,027,125	$55,098,832	$53,976,811

Available_For_Sale_Securities

Available For Sale Securities	12 Months Ended
	Dec. 31, 2013
Available For Sale Securities (Tables) [Abstract]	'
Available For Sale Securities	'
	Note 2. Available For Sale Securities
	MEDITECH follows the provisions of ASC 320-10, Investments - Debt and Equity Securities, which requires marketable securities be classified as trading, available-for-sale or held-to-maturity. MEDITECH classifies its marketable securities as available-for-sale and records them at fair value with any unrealized gains or losses, net of tax, reported as a component of shareholder equity. The fair value was determined based on quoted prices in active markets. ASC 320-10 requires that for each individual security classified as available-for-sale, a company shall determine whether a decline in fair value below the cost basis is temporary in nature. If the decline in fair value is not judged as such, the cost basis of the individual security shall be reduced to fair value and the amount of the write-down shall be reflected in earnings.
	MEDITECH follows the provisions of ASC 320-10-35 Subsequent Measurement, and evaluates its marketable securities for other-than-temporary impairment using an impairment model consistent with a debt security. The factors considered include the severity and duration of the loss, the intent and ability to hold the securities for an extended period of time until recovery, and whether issuers are current on dividend payments and maintain investment grade ratings. Finally, the effect of fluctuating interest rates, current economic and industry conditions, and the issuers' current financial position are also taken into consideration.
	MEDITECH follows the provisions of ASC 820-10, Fair Value Measurements and Disclosures, which provides for expanded disclosure and guidelines to determine fair market value of assets and liabilities. ASC 820-10 applies whenever other standards require or permit assets and liabilities to be measured at fair value, but does not expand the use of fair value in any new circumstances. MEDITECH's marketable securities represent assets measured at fair value on a recurring basis, and are considered Level 1 assets as defined by ASC 820-10.
	The following table indicates the cost net of write-downs, unrealized gains, unrealized losses and fair market value of MEDITECH's securities for the three years ended December 31. The unrealized gains and the unrealized losses have been accounted for within comprehensive income. MEDITECH has evaluated the unrealized losses as of December 31, 2013 and has concluded that the unrealized losses are temporary in nature.
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Cost net of write-downs	$231,177,996	$272,879,085	$279,666,014
	Unrealized gains	47,060,295	58,012,812	95,805,377
	Unrealized losses	-883,522	-1,236,625	-1,447,800
	Fair market value	$277,354,769	$329,655,272	$374,023,591

Comprehensive_Income_Presentat

Comprehensive Income Presentation	12 Months Ended
	Dec. 31, 2013
Comprehensive Income Presentation (Tables) [Abstract]	'
Comprehensive Income Presentation	'
	Note 15. Comprehensive Income Presentation
	Effective January 1, 2012 MEDITECH adopted the provisions of ASU 2011-05, Presentation of Comprehensive Income, which establishes standards for reporting comprehensive income and its components in financial statements. Comprehensive income is the total of net income and all other non-owner changes in equity including items such as net unrealized gains or losses on marketable securities classified as available for sale, foreign currency translation adjustments and minimum pension liability adjustments. In MEDITECH's case net income plus the change in net unrealized security gains or losses is shown as comprehensive income in the income statement.
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Change in unrealized holding gains	$17,642,621	$13,711,490	$24,646,378
	Reclassification of realized gains		-3,871,475	-7,568,621
	Change in net unrealized gains	$17,642,621	$9,840,015	$17,077,757

Deferred_Taxes

Deferred Taxes	12 Months Ended
	Dec. 31, 2013
Deferred Taxes (Tables) [Abstract]	'
Deferred Taxes	'
	Note 4. Deferred Taxes
	Deferred taxes relate to the earlier recognition of certain revenue and the later recognition of certain expense for tax purposes. Cumulative unrealized investment write-downs which had been reflected in the income statement are also a non-deductible expense for tax purposes. Such write-downs are considered capital losses which can only be offset by future capital gains. Current deferred tax assets consist of prepaid tax on accrued expenses. Long term deferred tax assets consist of prepaid tax on deposits and tax reserves. Current deferred tax liabilities consist primarily of tax on unrealized gains. Net deferred taxes changed from an asset to a liability during the current period primarily as a result of an increase in fair market value of marketable securities. The components of net deferred taxes for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Current deferred tax asset	$10,449,954	$9,457,643
	Long term deferred tax asset			$6,897,379
	Current deferred tax liability			($18,649,594)
	Net deferred tax asset (liability)	$10,449,954	$9,457,643	($11,752,215)

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share (Tables) [Abstract]	'
Earnings Per Share	'
	Note 14. Earnings Per Share
	MEDITECH follows the provisions of ASC 260-10, Earnings per Share, which requires reporting both basic and diluted earnings per share. MEDITECH has no common share equivalents such as preferred stock, warrants or stock options which would dilute earnings per share. Thus, earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the three years ended December 31. The average number of shares reflects the annual issuance of shares sold to staff members in February pursuant to the 2004 Stock Purchase Plan and the annual issuance of shares contributed to the MEDITECH Profit Sharing Trust in December.
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Net income	$124,001,302	$130,546,535	$133,328,172
	Average number of shares	36,411,749	36,777,380	37,102,883
	Earnings per share	$3.41	$3.55	$3.59

Equity_Method_Investments

Equity Method Investments	12 Months Ended
	Dec. 31, 2013
Equity Method Investments [Abstract]	'
Equity Method Investments	'
	Note 6. Equity Method Investments
	MEDITECH follows the provisions of ASC 323-10, Investments - Equity Method and Joint Ventures, and as such, accounts for the equity investment in Meditech South Africa in accordance with the cost method. Meditech South Africa licenses MEDITECH's software technology and re-licenses it to its respective customers. Meditech South Africa serves a market niche which is part of the overall medical market but is outside of the hospital market which MEDITECH serves. Meditech holds a fully collateralized mortgage note for a loan to Meditech South Africa to purchase land and a building used as its corporate headquarters. MEDITECH believes the fair value of this investment and loan balance approximates its December 31, 2013 carrying value.
	During the 2nd quarter 2007 MEDITECH acquired Patient Care Technologies, Inc. (PtCT), a company engaged in the development, manufacture, licensing and support of computer software products for the home health care market. MEDITECH accounted for this acquisition under the purchase method of accounting in accordance with ASC 805-10, Business Combinations. PtCT merged with and into MEDITECH effective December 31, 2009.
	During the 1st quarter 2011 MEDITECH acquired LSS Data Systems, Inc. (LSS), a company engaged in the development, manufacture, licensing and support of ambulatory information system software for physician practices. MEDITECH accounted for this acquisition under the purchase method of accounting in accordance with ASC 805-10, Business Combinations. LSS merged with and into MEDITECH effective December 31, 2013.
	MEDITECH follows the provisions of ASC 350-20-35 Intangibles and Goodwill Impairment Evaluation - Qualitative Testing. MEDITECH annually assesses qualitative factors of its goodwill and intangible assets for impairment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The evaluation assesses all relevant economic, industry, regulatory, and legal facts and circumstances as well as overall performance. If, after assessing the totality of such facts and circumstances, MEDITECH determines that it is more likely than not that the fair value of a reporting unit is not less than its carrying amount, then no further goodwill impairment testing is necessary. In accordance with ASC 805-10 and ASC 350-20-35, on December 31, 2013, MEDITECH concluded no impairment was needed on a qualitative testing basis. The components of other assets for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Investments	$1,440,061	$1,440,061	$1,440,061
	Mortgage Notes	929,000	828,200	716,000
	Goodwill & Intangibles	12,740,803	10,761,835	9,080,431
	Other	3,600,000	3,600,000	4,080,840
	Other assets	$18,709,864	$16,630,096	$15,317,332

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2013
Fixed Assets [Abstract]	'
Fixed Assets	'
	Note 5. Fixed Assets
	During the 3rd quarter of 2012 MEDITECH purchased land and an office building thereupon. During the 3rd quarter of 2013 MEDITECH purchased land, an office building thereupon and certain intangible assets. MEDITECH carries all fixed assets on a cost basis and provides for depreciation in amounts estimated to allocate the costs thereof under the following estimated useful lives. Maintenance costs are expensed as incurred. Improvements are capitalized and depreciated over the asset's useful life.
	Description	Useful Life
	Computer equipment	3-5 years
	Furniture and fixtures	7-10 years
	Buildings	31.5-40 years

Income_Tax_Accounting

Income Tax Accounting	12 Months Ended
	Dec. 31, 2013
Income Tax Accounting (Tables) [Abstract]	'
Income Tax Accounting	'
	Note 12. Income Tax Accounting
	MEDITECH follows the provisions of ASC 740-10, Accounting for Income Taxes. The current and deferred components of the State and Federal income taxes for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	State current	$14,734,339	$15,265,930	$7,520,390
	State deferred	-1,753,498	156,875	494,677
	State income tax	$12,980,841	$15,422,805	$8,015,067
	Federal current	$59,803,826	$65,300,099	$45,769,333
	Federal deferred	-4,878,678	835,441	211,549
	Federal income tax	$54,925,148	$66,135,540	$45,980,882

Income_Tax_Rate

Income Tax Rate	12 Months Ended
	Dec. 31, 2013
Income Tax Rate (Tables) [Abstract]	'
Income Tax Rate	'
	Note 13. Income Tax Rate
	The effective income tax rate for the three years ended December 31 is as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Statutory U.S. income tax rate	35.00%	35.00%	35.00%
	Increase in taxes resulting from state income
	taxes, net of federal income tax benefit	4.40%	4.70%	2.80%
	Dividend income exclusion	-1.50%	-1.50%	-1.80%
	Federal R&D tax credit	-2.10%	0.00%	-4.30%
	Other	-0.40%	0.30%	-2.90%
	Effective tax rate	35.40%	38.50%	28.80%

Litigation

Litigation	12 Months Ended
	Dec. 31, 2013
Litigation [Abstract]	'
Litigation	'
	Note 17. Litigation
	From time to time, the Company is a party to or may be threatened by litigation in the ordinary course of its business. The Company regularly analyzes current information, including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable and estimable liabilities for the eventual disposition of these matters. The Company is not a party to any material legal proceedings.

Other_Expense

Other Expense	12 Months Ended
	Dec. 31, 2013
Other Expense (Tables) [Abstract]	'
Other Expense	'
	Note 11. Other Expense
	Other expense consists primarily of rental costs and charitable contributions. The components of other expense for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Rental costs	$5,679,385	$4,614,584	$4,827,413
	Charitable contributions	820,000	840,000	890,000
	Other	502,353	567,320	1,310,688
	Other expense	$7,001,738	$6,021,904	$7,028,101

Other_Income

Other Income	12 Months Ended
	Dec. 31, 2013
Other Income (Tables) [Abstract]	'
Other Income	'
	Note 10. Other Income
	Other income consists primarily of rents, dividends, interest and realized marketable security activity. The components of other income for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Rents	$6,487,580	$5,618,754	$5,819,428
	Dividends	10,943,611	13,384,989	13,782,326
	Interest	190,332	109,439	216,102
	Security gains		9,386,721	11,906,501
	Other	-1,697,718	-1,978,968	-987,650
	Other income	$15,923,805	$26,520,935	$30,736,707

Qualified_Profit_Sharing_Plan

Qualified Profit Sharing Plan	12 Months Ended
	Dec. 31, 2013
Qualified Profit Sharing Plan [Abstract]	'
Qualified Profit Sharing Plan	'
	Note 16. Qualified Profit Sharing Plan
	MEDITECH has no obligation for post-employment or post-retirement benefits. MEDITECH maintains a qualified profit sharing plan which provides deferred compensation to substantially all of its staff members. Contributions to the plan are at the discretion of the Board of Directors and may be in the form of cash and shares of MEDITECH stock. The components of year-end contributions for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Cash	$5,840,000	$5,400,000	$10,875,000
	120,000 shares at $43 per share	5,160,000
	150,000 shares at $45 per share		6,750,000
	25,000 shares at $45 per share			1,125,000
	Contributions	$11,000,000	$12,150,000	$12,000,000

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncement	12 Months Ended
	Dec. 31, 2013
Recent Accounting Pronouncement [Abstract]	'
Recent Accounting Pronouncement	'
	Note 18. Recent Accounting Pronouncement
	In May 2014, the FASB issued updated accounting guidance on revenue recognition. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. This guidance is effective for annual reporting periods, and any interim periods within those annual periods, that begin after December 15, 2016 and allows for either full retrospective or modified retrospective application, with early adoption not permitted. Accordingly, the standard is effective for the Company on January 1, 2017. The Company is currently evaluating the adoption method it will apply and the impact that this guidance will have on its financial statements and related disclosures.

Reserve_for_Doubtful_Accounts

Reserve for Doubtful Accounts	12 Months Ended
	Dec. 31, 2013
Reserve for Doubtful Accounts [Abstract]	'
Reserve for Doubtful Accounts	'
	Note 3. Reserve for Doubtful Accounts
	The components of the reserve for doubtful accounts for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Reserve at beginning of year	$1,250,000	$1,500,000	$1,575,000
	Amounts charged to expense	321,585	144,434	7,714
	Amounts written off	-71,585	-69,434	-7,714
	Reserve at end of year	$1,500,000	$1,575,000	$1,575,000

Segment_Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2013
Segment Reporting (Tables) [Abstract]	'
Segment Reporting	'
	Note 9. Segment Reporting
	MEDITECH follows the provisions of ASC 280-10, Segment Reporting. Based on the criteria set forth in ASC 280-10, MEDITECH currently operates in one operating segment, medical software and services. MEDITECH derives its revenue from the sale and support of one group of similar products and services. All of MEDITECH's assets are located within the United States. The following table indicates the percentage of revenue based on customer location plus the percentage of revenue from the largest customer for the three years ended December 31 is as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Total revenues	$545,224,384	$597,838,787	$579,645,457
	United States	90%	91%	88%
	Canada	8%	8%	10%
	All Others	2%	1%	2%
	Largest customer	7%	7%	8%

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies (Policies) [Abstract]	'
Significant Accounting Policies	'
	Note 1. Significant Accounting Policies
	MEDITECH is engaged in the development, manufacture, licensing and support of computer software products for the hospital market. The principal market for its products consists of health care providers located primarily in the United States and Canada.
	The accompanying consolidated financial statements reflect the application of certain accounting policies discussed below. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	The consolidated financial statements include MEDITECH's wholly owned subsidiary, LSS Data Systems, Inc., in accordance with Accounting Standards Codification (ASC) 810, Consolidation of Financial Statements.
	(a) Revenue Recognition
	MEDITECH follows the provisions of ASC 985-605-25, Software Revenue Recognition, and ASC 605-35-25, Construction-Type and Production-Type Contracts. MEDITECH enters into perpetual software license contracts which provide for a customer deposit upon contract execution, milestone billings during the implementation phase and fixed monthly support fees thereafter.
	MEDITECH classifies software fees and related implementation fees together as product revenue in the statement of income. Such revenue is recognized when persuasive evidence of an agreement exists, the fee is fixed or determinable, completion of each contract milestone has occurred, and collection of the fee is probable. Determining whether and when some of these criteria have been satisfied often involves assumptions and judgments that can have a significant impact on the timing and amount of revenue recognized. The primary factors taken into consideration involve tracking and measuring progress to complete software delivery and installation, training on the use the software, interfacing the software with other vendor software, and timing when the software becomes operational at the customer's site. Once a contract milestone is deemed completed the customer is invoiced and revenue is recognized. MEDITECH classifies post-implementation support fees as service revenue in the statement of income and recognizes these fees as revenue when the related services are rendered.
	MEDITECH follows the provisions of ASC 605-45-15, Reimbursements Received for Out-of-Pocket Expenses. Such expenses are characterized as product revenue with offsetting operating expense included in the consolidated income statement.
	Revenue Recognition Adjustments
	MEDITECH evaluated the accounting for revenue recognition and subsequently determined certain revenues and associated expenses, including other identified errors, were not calculated correctly. Such cumulative errors were not material on a quantitative or qualitative basis using both the roll-over and iron-curtain methods as defined in SAB No. 108. At December 31, 2013 the error correction amounted to adjustments to total revenue, operating expense, pretax income and net income and are not considered material to current or prior consolidated financial statements. Such error correction adjustments are as follows.
	Error Correction	1 year
	Adjustments	Dec 31, 2013
	Total Revenue	-17,263,000
	Operating Expense	-4,963,000
	Pretax Income	-12,305,000
	Net Income	-4,928,000
	(b) Software Development Costs
	MEDITECH follows the provisions of ASC 985-20, Accounting for the Costs of Computer Software to Be Sold, Leased or Marketed. ASC 985-20 establishes standards for capitalizing software development costs incurred after technological feasibility of the software development projects is established and the realizability of such capitalized costs through future operations is expected, if such costs become material. To date, development costs incurred by MEDITECH after technological feasibility has been established have been immaterial and as such have been charged to operations as incurred.
	(c) Cash and Equivalents
	MEDITECH considers all highly liquid investments purchased with original maturities of 90 days or less to be cash equivalents.
	(d) Common Stock Dividend Policy
	MEDITECH's Board of Directors has full discretion regarding the timing and amounts of dividends paid on common stock.
	(e) Fair Value of Financial Instruments and Concentration of Credit Risk
	The carrying value of MEDITECH's cash and cash equivalents, accounts receivable and accounts payable approximates their fair value due to the short-term nature of these financial instruments. MEDITECH's marketable securities are carried at fair value.
	Financial instruments that potentially subject MEDITECH to concentrations of credit risk are principally cash, cash equivalents, marketable securities and accounts receivable. MEDITECH places its cash and cash equivalents in highly rated institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom MEDITECH makes substantial sales. To reduce risk, MEDITECH routinely assesses the financial strength of its customers and, as a result, believes that its accounts receivable credit risk exposure is limited. MEDITECH maintains a reserve for doubtful accounts but historically has not experienced any significant credit losses related to an individual customer or groups of customers. As December 31, 2013 HCA-The Healthcare Company represented 12% of the outstanding trade receivables.

Supplemental_Data

Supplemental Data	12 Months Ended
	Dec. 31, 2013
Supplemental Data [Abstract]	'
Supplemental Data	'
	Note 19. Supplemental Data
	Unaudited operating results by quarter for the three years ended December 31 are as follows:
		1st Q	2nd Q	3rd Q	4th Q	2011
	Total revenue	$123,805,092	$136,258,047	$141,054,763	$144,106,482	$545,224,384
	Operating income	41,084,958	46,476,482	48,188,968	47,234,816	182,985,224
	Net income	27,904,364	31,199,385	32,407,718	32,489,835	124,001,302
	Net income per share	$0.77	$0.86	$0.89	$0.89	$3.41
		1st Q	2nd Q	3rd Q	4th Q	2012
	Total revenue	$145,866,167	$149,004,750	$152,110,955	$150,856,915	$597,838,787
	Operating income	46,781,499	47,911,499	49,368,821	47,544,031	191,605,849
	Net income	30,843,225	33,797,188	33,903,606	32,002,517	130,546,535
	Net income per share	$0.84	$0.92	$0.92	$0.87	$3.55
		1st Q	2nd Q	3rd Q	4th Q	2013
	Total revenue	$151,183,057	$144,033,794	$138,421,645	$146,006,961	$579,645,457
	Operating income	45,610,303	40,385,314	39,096,189	38,523,709	163,615,515
	Net income	35,479,098	28,194,508	31,806,968	37,847,598	133,328,172
	Net income per share	$0.96	$0.76	$0.86	$1.01	$3.59

Tax_Reserves

Tax Reserves	12 Months Ended
	Dec. 31, 2013
Tax Reserves (Tables) [Abstract]	'
Tax Reserves	'
	Note 8. Tax Reserves
	Tax reserves relate to the uncertainty of domestic production activities deduction and state nexus. Key judgments are reviewed annually and adjusted to reflect current assessments. The years 2010 through 2013 are subject to examination by the IRS, and various years are subject to examination by state tax authorities. MEDITECH accounts for the annual change in tax reserves as part of its provision for income taxes. The components of tax reserves for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Potential tax assessment	$8,427,512	$11,407,396	$8,597,502
	Interest and penalties	4,136,525	6,371,779	9,914,775
	Tax reserves	$12,564,037	$17,779,175	$18,512,277

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies (Policies) [Abstract]	'
Significant Accounting Policies	'
	MEDITECH is engaged in the development, manufacture, licensing and support of computer software products for the hospital market. The principal market for its products consists of health care providers located primarily in the United States and Canada.
	The accompanying consolidated financial statements reflect the application of certain accounting policies discussed below. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	The consolidated financial statements include MEDITECH's wholly owned subsidiary, LSS Data Systems, Inc., in accordance with Accounting Standards Codification (ASC) 810, Consolidation of Financial Statements.
	(a) Revenue Recognition
	MEDITECH follows the provisions of ASC 985-605-25, Software Revenue Recognition, and ASC 605-35-25, Construction-Type and Production-Type Contracts. MEDITECH enters into perpetual software license contracts which provide for a customer deposit upon contract execution, milestone billings during the implementation phase and fixed monthly support fees thereafter.
	MEDITECH classifies software fees and related implementation fees together as product revenue in the statement of income. Such revenue is recognized when persuasive evidence of an agreement exists, the fee is fixed or determinable, completion of each contract milestone has occurred, and collection of the fee is probable. Determining whether and when some of these criteria have been satisfied often involves assumptions and judgments that can have a significant impact on the timing and amount of revenue recognized. The primary factors taken into consideration involve tracking and measuring progress to complete software delivery and installation, training on the use the software, interfacing the software with other vendor software, and timing when the software becomes operational at the customer's site. Once a contract milestone is deemed completed the customer is invoiced and revenue is recognized. MEDITECH classifies post-implementation support fees as service revenue in the statement of income and recognizes these fees as revenue when the related services are rendered.
	MEDITECH follows the provisions of ASC 605-45-15, Reimbursements Received for Out-of-Pocket Expenses. Such expenses are characterized as product revenue with offsetting operating expense included in the consolidated income statement.
	Revenue Recognition Adjustments
	MEDITECH evaluated the accounting for revenue recognition and subsequently determined certain revenues and associated expenses, including other identified errors, were not calculated correctly. Such cumulative errors were not material on a quantitative or qualitative basis using both the roll-over and iron-curtain methods as defined in SAB No. 108. At December 31, 2013 the error correction amounted to adjustments to total revenue, operating expense, pretax income and net income and are not considered material to current or prior consolidated financial statements. Such error correction adjustments are as follows.
	Error Correction	1 year
	Adjustments	Dec 31, 2013
	Total Revenue	-17,263,000
	Operating Expense	-4,963,000
	Pretax Income	-12,305,000
	Net Income	-4,928,000
	(b) Software Development Costs
	MEDITECH follows the provisions of ASC 985-20, Accounting for the Costs of Computer Software to Be Sold, Leased or Marketed. ASC 985-20 establishes standards for capitalizing software development costs incurred after technological feasibility of the software development projects is established and the realizability of such capitalized costs through future operations is expected, if such costs become material. To date, development costs incurred by MEDITECH after technological feasibility has been established have been immaterial and as such have been charged to operations as incurred.
	(c) Cash and Equivalents
	MEDITECH considers all highly liquid investments purchased with original maturities of 90 days or less to be cash equivalents.
	(d) Common Stock Dividend Policy
	MEDITECH's Board of Directors has full discretion regarding the timing and amounts of dividends paid on common stock.
	(e) Fair Value of Financial Instruments and Concentration of Credit Risk
	The carrying value of MEDITECH's cash and cash equivalents, accounts receivable and accounts payable approximates their fair value due to the short-term nature of these financial instruments. MEDITECH's marketable securities are carried at fair value.
	Financial instruments that potentially subject MEDITECH to concentrations of credit risk are principally cash, cash equivalents, marketable securities and accounts receivable. MEDITECH places its cash and cash equivalents in highly rated institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom MEDITECH makes substantial sales. To reduce risk, MEDITECH routinely assesses the financial strength of its customers and, as a result, believes that its accounts receivable credit risk exposure is limited. MEDITECH maintains a reserve for doubtful accounts but historically has not experienced any significant credit losses related to an individual customer or groups of customers. As December 31, 2013 HCA-The Healthcare Company represented 12% of the outstanding trade receivables.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses (Tables) [Abstract]	'
Accrued Expenses	'
	The components of accrued expenses for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Accrued bonuses	$43,750,000	$47,628,625	$45,985,000
	Accrued vacation	4,690,000	4,707,000	4,813,000
	Other	2,587,125	2,763,207	3,178,811
	Accrued expenses	$51,027,125	$55,098,832	$53,976,811

Available_For_Sale_Securities_

Available For Sale Securities (Tables)	12 Months Ended
	Dec. 31, 2013
Available For Sale Securities (Tables) [Abstract]	'
Available For Sale Securities	'
	The following table indicates the cost net of write-downs, unrealized gains, unrealized losses and fair market value of MEDITECH's securities for the three years ended December 31. The unrealized gains and the unrealized losses have been accounted for within comprehensive income. MEDITECH has evaluated the unrealized losses as of December 31, 2013 and has concluded that the unrealized losses are temporary in nature.
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Cost net of write-downs	$231,177,996	$272,879,085	$279,666,014
	Unrealized gains	47,060,295	58,012,812	95,805,377
	Unrealized losses	-883,522	-1,236,625	-1,447,800
	Fair market value	$277,354,769	$329,655,272	$374,023,591

Comprehensive_Income_Presentat1

Comprehensive Income Presentation (Tables)	12 Months Ended
	Dec. 31, 2013
Comprehensive Income Presentation (Tables) [Abstract]	'
Comprehensive Income Presentation	'
	Effective January 1, 2012 MEDITECH adopted the provisions of ASU 2011-05, Presentation of Comprehensive Income, which establishes standards for reporting comprehensive income and its components in financial statements. Comprehensive income is the total of net income and all other non-owner changes in equity including items such as net unrealized gains or losses on marketable securities classified as available for sale, foreign currency translation adjustments and minimum pension liability adjustments. In MEDITECH's case net income plus the change in net unrealized security gains or losses is shown as comprehensive income in the income statement.
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Change in unrealized holding gains	$17,642,621	$13,711,490	$24,646,378
	Reclassification of realized gains		-3,871,475	-7,568,621
	Change in net unrealized gains	$17,642,621	$9,840,015	$17,077,757

Deferred_Taxes_Tables

Deferred Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Taxes (Tables) [Abstract]	'
Deferred taxes	'
	Deferred taxes relate to the earlier recognition of certain revenue and the later recognition of certain expense for tax purposes. Cumulative unrealized investment write-downs which had been reflected in the income statement are also a non-deductible expense for tax purposes. Such write-downs are considered capital losses which can only be offset by future capital gains. Current deferred tax assets consist of prepaid tax on accrued expenses. Long term deferred tax assets consist of prepaid tax on deposits and tax reserves. Current deferred tax liabilities consist primarily of tax on unrealized gains. Net deferred taxes changed from an asset to a liability during the current period primarily as a result of an increase in fair market value of marketable securities. The components of net deferred taxes for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Current deferred tax asset	$10,449,954	$9,457,643
	Long term deferred tax asset			$6,897,379
	Current deferred tax liability			($18,649,594)
	Net deferred tax asset (liability)	$10,449,954	$9,457,643	($11,752,215)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share (Tables) [Abstract]	'
Earnings Per Share	'
	MEDITECH follows the provisions of ASC 260-10, Earnings per Share, which requires reporting both basic and diluted earnings per share. MEDITECH has no common share equivalents such as preferred stock, warrants or stock options which would dilute earnings per share. Thus, earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the three years ended December 31. The average number of shares reflects the annual issuance of shares sold to staff members in February pursuant to the 2004 Stock Purchase Plan and the annual issuance of shares contributed to the MEDITECH Profit Sharing Trust in December.
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Net income	$124,001,302	$130,546,535	$133,328,172
	Average number of shares	36,411,749	36,777,380	37,102,883
	Earnings per share	$3.41	$3.55	$3.59

Equity_Method_Investments_Tabl

Equity Method Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Equity Method Investments (Tables) [Abstract]	'
Equity Method Investments	'
	MEDITECH follows the provisions of ASC 350-20-35 Intangibles and Goodwill Impairment Evaluation - Qualitative Testing. MEDITECH annually assesses qualitative factors of its goodwill and intangible assets for impairment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The evaluation assesses all relevant economic, industry, regulatory, and legal facts and circumstances as well as overall performance. If, after assessing the totality of such facts and circumstances, MEDITECH determines that it is more likely than not that the fair value of a reporting unit is not less than its carrying amount, then no further goodwill impairment testing is necessary. In accordance with ASC 805-10 and ASC 350-20-35, on December 31, 2013, MEDITECH concluded no impairment was needed on a qualitative testing basis. The components of other assets for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Investments	$1,440,061	$1,440,061	$1,440,061
	Mortgage Notes	929,000	828,200	716,000
	Goodwill & Intangibles	12,740,803	10,761,835	9,080,431
	Other	3,600,000	3,600,000	4,080,840
	Other assets	$18,709,864	$16,630,096	$15,317,332

Income_Tax_Accounting_Tables

Income Tax Accounting (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Accounting (Tables) [Abstract]	'
Income Tax Accounting	'
	MEDITECH follows the provisions of ASC 740-10, Accounting for Income Taxes. The current and deferred components of the State and Federal income taxes for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	State current	$14,734,339	$15,265,930	$7,520,390
	State deferred	-1,753,498	156,875	494,677
	State income tax	$12,980,841	$15,422,805	$8,015,067
	Federal current	$59,803,826	$65,300,099	$45,769,333
	Federal deferred	-4,878,678	835,441	211,549
	Federal income tax	$54,925,148	$66,135,540	$45,980,882

Income_Tax_Rate_Tables

Income Tax Rate (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Rate (Tables) [Abstract]	'
Income Tax Rate	'
	The effective income tax rate for the three years ended December 31 is as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Statutory U.S. income tax rate	35.00%	35.00%	35.00%
	Increase in taxes resulting from state income
	taxes, net of federal income tax benefit	4.40%	4.70%	2.80%
	Dividend income exclusion	-1.50%	-1.50%	-1.80%
	Federal R&D tax credit	-2.10%	0.00%	-4.30%
	Other	-0.40%	0.30%	-2.90%
	Effective tax rate	35.40%	38.50%	28.80%

Other_Expense_Tables

Other Expense (Tables)	12 Months Ended
	Dec. 31, 2013
Other Expense (Tables) [Abstract]	'
Other Expense	'
	Other expense consists primarily of rental costs and charitable contributions. The components of other expense for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Rental costs	$5,679,385	$4,614,584	$4,827,413
	Charitable contributions	820,000	840,000	890,000
	Other	502,353	567,320	1,310,688
	Other expense	$7,001,738	$6,021,904	$7,028,101

Other_Income_Tables

Other Income (Tables)	12 Months Ended
	Dec. 31, 2013
Other Income (Tables) [Abstract]	'
Other Income	'
	Other income consists primarily of rents, dividends, interest and realized marketable security activity. The components of other income for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Rents	$6,487,580	$5,618,754	$5,819,428
	Dividends	10,943,611	13,384,989	13,782,326
	Interest	190,332	109,439	216,102
	Security gains		9,386,721	11,906,501
	Other	-1,697,718	-1,978,968	-987,650
	Other income	$15,923,805	$26,520,935	$30,736,707

Qualified_Profit_Sharing_Plan_

Qualified Profit Sharing Plan (Tables)	12 Months Ended
	Dec. 31, 2013
Qualified Profit Sharing Plan (Tables) [Abstract]	'
Qualified Profit Sharing Plan	'
	MEDITECH has no obligation for post-employment or post-retirement benefits. MEDITECH maintains a qualified profit sharing plan which provides deferred compensation to substantially all of its staff members. Contributions to the plan are at the discretion of the Board of Directors and may be in the form of cash and shares of MEDITECH stock. The components of year-end contributions for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Cash	$5,840,000	$5,400,000	$10,875,000
	120,000 shares at $43 per share	5,160,000
	150,000 shares at $45 per share		6,750,000
	25,000 shares at $45 per share			1,125,000
	Contributions	$11,000,000	$12,150,000	$12,000,000

Reserve_for_Doubtful_Accounts_

Reserve for Doubtful Accounts (Tables)	12 Months Ended
	Dec. 31, 2013
Reserve for Doubtful Accounts (Tables) [Abstract]	'
Reserve for Doubtful Accounts	'
	The components of the reserve for doubtful accounts for the three years ended December 31 are as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Reserve at beginning of year	$1,250,000	$1,500,000	$1,575,000
	Amounts charged to expense	321,585	144,434	7,714
	Amounts written off	-71,585	-69,434	-7,714
	Reserve at end of year	$1,500,000	$1,575,000	$1,575,000

Segment_Reporting_Tables

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting (Tables) [Abstract]	'
Segment Reporting	'
	MEDITECH follows the provisions of ASC 280-10, Segment Reporting. Based on the criteria set forth in ASC 280-10, MEDITECH currently operates in one operating segment, medical software and services. MEDITECH derives its revenue from the sale and support of one group of similar products and services. All of MEDITECH's assets are located within the United States. The following table indicates the percentage of revenue based on customer location plus the percentage of revenue from the largest customer for the three years ended December 31 is as follows:
		1 year	1 year	1 year
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Total revenues	$545,224,384	$597,838,787	$579,645,457
	United States	90%	91%	88%
	Canada	8%	8%	10%
	All Others	2%	1%	2%
	Largest customer	7%	7%	8%

Tax_Reserves_Tables

Tax Reserves (Tables)	12 Months Ended
	Dec. 31, 2013
Tax Reserves (Tables) [Abstract]	'
Tax Reserves	'
	Tax reserves relate to the uncertainty of domestic production activities deduction and state nexus. Key judgments are reviewed annually and adjusted to reflect current assessments. The years 2010 through 2013 are subject to examination by the IRS, and various years are subject to examination by state tax authorities. MEDITECH accounts for the annual change in tax reserves as part of its provision for income taxes. The components of tax reserves for the three years ended December 31 are as follows:
		Dec 31, 2011	Dec 31, 2012	Dec 31, 2013
	Potential tax assessment	$8,427,512	$11,407,396	$8,597,502
	Interest and penalties	4,136,525	6,371,779	9,914,775
	Tax reserves	$12,564,037	$17,779,175	$18,512,277

Accrued_Expenses_Details_1

Accrued Expenses (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accrued Expenses [Abstract]	'	'	'
Accrued bonuses	$45,985,000	$47,628,625	$43,750,000
Accrued vacation	4,813,000	4,707,000	4,690,000
Other	3,178,811	2,763,207	2,587,125
Accrued expenses	$53,976,811	$55,098,832	$51,027,125

Available_For_Sale_Securities_1

Available For Sale Securities (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Available For Sale Securities (Tables) [Abstract]	'	'	'
Cost net of write-downs	$279,666,014	$272,879,085	$231,177,996
Unrealized gains	95,805,377	58,012,812	47,060,295
Unrealized losses	-1,447,800	-1,236,625	-883,522
Fair market value	$374,023,591	$329,655,272	$277,354,769

Comprehensive_Income_Presentat2

Comprehensive Income Presentation (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Comprehensive Income Note [Abstract] (Deprecated 2011-01-31)	'	'	'
Change in unrealized holding gains	$24,646,378	$13,711,490	$17,642,621
Reclassification of realized gains	-7,568,621	-3,871,475	'
Change in net unrealized gains	$17,077,757	$9,840,015	$17,642,621

Deferred_Taxes_Details_1

Deferred Taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Taxes (Tables) [Abstract]	'	'	'
Current deferred tax asset	'	$9,457,643	$10,449,954
Long term deferred tax asset	6,897,379	'	'
Current deferred tax liability	-18,649,594	'	'
Net deferred tax asset (liability)	($11,752,215)	$9,457,643	$10,449,954

Earnings_Per_Share_Details_1

Earnings Per Share (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share (Tables) [Abstract]	'	'	'
Net income	$133,328,172	$130,546,535	$124,001,302
Average number of shares	37,102,883	36,777,380	36,411,749
Earnings per share	$3.59	$3.55	$3.41

Equity_Method_Investments_Deta

Equity Method Investments (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity Method Investments [Abstract]	'	'	'
Investments	$1,440,061	$1,440,061	$1,440,061
Mortgage Notes	716,000	828,200	929,000
Goodwill & Intangibles	9,080,431	10,761,835	12,740,803
Other	4,080,840	3,600,000	3,600,000
Other assets	$15,317,332	$16,630,096	$18,709,864

Income_Tax_Accounting_Details_

Income Tax Accounting (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Accounting (Tables) [Abstract]	'	'	'
State current	$7,520,390	$15,265,930	$14,734,339
State deferred	494,677	156,875	-1,753,498
State income tax	8,015,067	15,422,805	12,980,841
Federal current	45,769,333	65,300,099	59,803,826
Federal deferred	211,549	835,441	-4,878,678
Federal income tax	$45,980,882	$66,135,540	$54,925,148

Income_Tax_Rate_Details_1

Income Tax Rate (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Rate (Tables) [Abstract]	'	'	'
Statutory U.S. income tax rate	$35	$35	$35
Increase in taxes resulting from state income	'	'	'
taxes, net of federal income tax benefit	2.8	4.7	4.4
Dividend income exclusion	-1.8	-1.5	-1.5
Federal R&D tax credit	-4.30%	0.00%	-2.10%
Other	-2.9	0.3	-0.4
Effective tax rate	$28.80	$38.50	$35.40

Other_Expense_Details_1

Other Expense (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Expense (Tables) [Abstract]	'	'	'
Rental costs	$4,827,413	$4,614,584	$5,679,385
Charitable contributions	890,000	840,000	820,000
Other	1,310,688	567,320	502,353
Other expense	$7,028,101	$6,021,904	$7,001,738

Other_Income_Details_1

Other Income (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Income (Tables) [Abstract]	'	'	'
Rents	$5,819,428	$5,618,754	$6,487,580
Dividends	13,782,326	13,384,989	10,943,611
Interest	216,102	109,439	190,332
Security gains	11,906,501	9,386,721	'
Other	-987,650	-1,978,968	-1,697,718
Other income	$30,736,707	$26,520,935	$15,923,805

Qualified_Profit_Sharing_Plan_1

Qualified Profit Sharing Plan (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Qualified Profit Sharing Plan [Abstract]	'	'	'
Cash	$10,875,000	$5,400,000	$5,840,000
120,000 shares at $43 per share	'	'	5,160,000
150,000 shares at $45 per share	'	6,750,000	'
25,000 shares at $45 per share	1,125,000	'	'
Contributions	$12,000,000	$12,150,000	$11,000,000

Reserve_for_Doubtful_Accounts_1

Reserve for Doubtful Accounts (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reserve for Doubtful Accounts [Abstract]	'	'	'
Reserve at beginning of year	$1,575,000	$1,500,000	$1,250,000
Amounts charged to expense	7,714	144,434	321,585
Amounts written off	-7,714	-69,434	-71,585
Reserve at end of year	$1,575,000	$1,575,000	$1,500,000

Segment_Reporting_Details_1

Segment Reporting (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting (Tables) [Abstract]	'	'	'
Total revenues	$579,645,457	$597,838,787	$545,224,384
United States	88.00%	91.00%	90.00%
Canada	10.00%	8.00%	8.00%
All Others	2	1	2
Largest customer	$8	$7	$7

Tax_Reserves_Details_1

Tax Reserves (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Tax Reserves (Tables) [Abstract]	'	'	'
Potential tax assessment	$8,597,502	$11,407,396	$8,427,512
Interest and penalties	9,914,775	6,371,779	4,136,525
Tax reserves	$18,512,277	$17,779,175	$12,564,037